Freeport-McMoRan's 4Q16 Earnings: The Word on Wall Street
Analysts expect Freeport to post EBITDA of ~$1.7 billion in 4Q16, as compared to $0.89 billion in 4Q15 and $1.3 billion in 3Q16.
Both Freeport-McMoRan’s (FCX) and Glencore (GLNCY) suffered from the same issues last year—falling commodity prices and higher leverage ratios (TCK).
analysts expect Freeport-McMoRan (FCX) to post revenue of $4.34 billion in 4Q16 and $4.20 billion in 1Q17.
Freeport stock saw significant upward movement in 4Q16.
Johnson & Johnson’s (JNJ) 4Q16 segment-wise performance is expected to be positive across all segments including pharmaceuticals, consumer, and medical devices segments.
JNJ stock has returned nearly 18.1% in the last 12 months, and analysts estimate the stock might rise 9% over the next 12 months.
Johnson & Johnson (JNJ) has restructured its business over the last few years and divested some low profitability products.
Johnson & Johnson’s (JNJ) consumer healthcare segment includes baby care, oral care, skin care, over-the-counter products, women’s health, and wound care franchises.
Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.
Johnson & Johnson’s (JNJ) pharmaceuticals segment consists of its immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics franchises.
Analysts expect a growth of 2.5% in Johnson & Johnson’s (JNJ) 4Q16 revenues to ~$18.3 billion, following an increase in sales of its blockbuster drugs including Remicade, Stelara, Olysio, and Zytiga.
Johnson & Johnson is set to release its 4Q16 earnings on January 24, 2017.
On January 19, 2017, NextEra Energy (NEE) stock was trading at a 2% premium and at a 1% discount to its 50-day and 200-day moving averages, respectively.
NextEra Energy (NEE) is estimated to report earnings of $1.31 per share for 4Q16. It reported earnings of $1.09 per share in 4Q15.
NEE’s dividends have grown by more than 8%, compounded annually, since 2005.
On January 19, 2017, NextEra Energy (NEE) was trading at an EV-to-EBITDA ratio of 11x. Its five-year historical average valuation multiple stands near 11x.
Renewables giant NextEra is estimated to report total revenues of ~$4.6 billion for 4Q16, as compared to total revenues of just over $4 billion in 4Q15.
Earnings trend Colgate-Palmolive (CL) beat analysts’ estimates in seven of the last 11 quarters. The company delivered adjusted EPS (earnings per share) of $0.73 in 3Q16, exceeding analysts’ earnings estimate…
Analyst coverage As of January 17, 2017, of the 20 analysts covering Colgate-Palmolive (CL), three analysts, or 15%, had rated the stock as a “buy.” The stock was rated “hold”…
12-month forward price-to-earnings multiple As of January 17, Colgate-Palmolive (CL) was trading at a 12-month forward PE (price-to-earnings) multiple of 22.2x. The company is currently trading at a higher valuation…